Daiichi Sankyo’s pexidartinib is first FDA-approved drug for rare tumourDaiichi Sankyo’s pexidartinib has become the first FDA-approved therapy for tenosynovial giant cell tumour (TGCT), a rare form Share XDaiichi Sankyo’s pexidartinib is first FDA-approved drug for rare tumourhttps://pharmaphorum.com/news/daiichi-sankyos-pexidartinib-is-first-fda-approved-drug-for-rare-tumour/
Daiichi waits on FDA as AML drug quizartinib approved in JapanThe Japanese regulator has approved Daiichi Sankyo’s quizartinib for certain patients with acute myeloid leukaemia (AML), amid doubts Share XDaiichi waits on FDA as AML drug quizartinib approved in Japanhttps://pharmaphorum.com/news/daiichi-waits-on-fda-as-aml-drug-quizartinib-approved-in-japan/
Daiichi Sankyo in talks over OTC unit sale – reportsDaiichi Sankyo is in talks with several companies over a sale of its over-the-counter (OTC) business, according to Share XDaiichi Sankyo in talks over OTC unit sale – reportshttps://pharmaphorum.com/news/daiichi-sankyo-in-talks-over-otc-unit-sale-reports/
Oncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and moreAZ and Daiichi Sankyo announced positive top-line results from the pivotal phase 2 DESTINY-Breast01 trial of trastuzumab deruxtecan, Share XOncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and morehttps://pharmaphorum.com/views-and-analysis/oncology-round-up-az-and-daiichi-score-key-trial-win-with-breast-cancer-antibody-and-more/
FDA advisors reject one Daiichi Sankyo cancer drug, back anotherDaiichi Sankyo had a day of mixed fortunes after advisers to the US regulator voted against approval for Share XFDA advisors reject one Daiichi Sankyo cancer drug, back anotherhttps://pharmaphorum.com/news/fda-advisors-reject-one-daiichi-sankyo-cancer-drug-back-another/
AZ and Daiichi to file new breast cancer drug after trial successIn March AstraZeneca asked investors for $3.5 billion to fund a collaboration with Daiichi Sankyo over a new Share XAZ and Daiichi to file new breast cancer drug after trial successhttps://pharmaphorum.com/news/az-and-daiichi-to-file-trastuzumab-deruxtecan/
AZ signs multi-billion cancer R&D deal with Daiichi SankyoAstraZeneca is to raise $3.5 billion to fund a global development and marketing collaboration with Daiichi Sankyo, for Share XAZ signs multi-billion cancer R&D deal with Daiichi Sankyohttps://pharmaphorum.com/news/az-signs-multi-billion-cancer-rd-deal-with-daiichi-sankyo/
Lixiana hits the mark in catheter ablation trialDaiichi Sankyo’s Lixiana was a late entrant to the novel oral anticoagulant (NOAC) category, but the Japanese drugmaker Share XLixiana hits the mark in catheter ablation trialhttps://pharmaphorum.com/news/lixiana-hits-the-mark-in-catheter-ablation-trial/
Daiichi gets speedy FDA review for rare cancer drugDaiichi Sankyo has been given a priority review from the FDA for pexidartinib, which is vying to become Share XDaiichi gets speedy FDA review for rare cancer drughttps://pharmaphorum.com/news/daiichi-speedy-fda-review-rare-cancer-drug/
